

This listing of claims will replace all prior versions of claims in the application.

Listing of Claims: Please amend the claims as follows:

**We claim:**

**Claim 1. (Previously Presented)** A method for impairing cumulus expansion and oocyte maturation, comprising antagonizing the EP<sub>2</sub> receptor and inhibiting cyclooxygenase COX-2.

**Claim 2. (Previously Presented)** The method of claim 1, comprising antagonizing the EP<sub>2</sub> receptor by the EP<sub>2</sub> receptor antagonist AH6809.

**Claim 3. (Previously Presented)** The method of claim 1, comprising administering a composition comprising an EP<sub>2</sub> receptor antagonist and at least one COX inhibitor.

**Claim 4. (Previously Presented)** A method of fertility control in a woman comprising administering an EP<sub>2</sub> receptor antagonist and a cyclooxygenase COX-2 inhibitor.

**Claim 5. (Previously Presented)** The method according to claim 4, comprising administering an EP<sub>2</sub> receptor antagonist.

**Claim 6. (Previously Presented)** The method according to claim 4, comprising administering a composition comprising an EP<sub>2</sub> receptor antagonist and at least one COX inhibitor.

**Claim 7. (Previously Presented)** The method according to claim 6, wherein said COX inhibitor is selective for cyclooxygenase-2 (COX-2).

**Claim 8. (Previously Presented)** The method according to claim 6 wherein the COX inhibitor is Celecoxib, Ceracoxib, Parecoxib, Rofecoxib, Valdecoxib, NS-398 or Etoricoxib.

**Claim 9. (Previously Presented)** The method according to claim 6 wherein the COX inhibitor is Celecoxib or Rofecoxib.

**Claim 10. (Previously Presented)** The method according to claim 6 comprising administering said composition orally.

**Claim 11. (Previously Presented)** The method of claim 1 for achieving fertility control in a woman.

**Claim 12. (Previously Presented)** The method according to claim 4, comprising antagonizing the EP<sub>2</sub> receptor by the EP<sub>2</sub> receptor antagonist AH6809.

**Claim 13. (Previously Presented)** The method according to claim 3 comprising administering the EP<sub>2</sub> receptor antagonist AH6809 and at least one COX inhibitor which is Celecoxib, Ceracoxib, Parecoxib, Rofecoxib, Valdecoxib, NS-398 or Etoricoxib.

**Claim 14. (Previously Presented)** The method according to claim 6 comprising administering the EP<sub>2</sub> receptor antagonist AH6809 and at least one COX inhibitor which is Celecoxib, Ceracoxib, Parecoxib, Rofecoxib, Valdecoxib, NS-398 or Etoricoxib.

**Claim 15. (Previously Presented)** The method according to claim 3 comprising administering the EP<sub>2</sub> receptor antagonist AH6809 and at least one COX inhibitor which is Celecoxib or Rofecoxib.

**Claim 16. (Previously Presented)** The method according to claim 6 comprising administering the EP<sub>2</sub> receptor antagonist AH6809 and at least one COX inhibitor which is Celecoxib or Rofecoxib.

**Claim 17. (Previously Presented)** A method for impairing cumulus expansion and oocyte maturation comprising antagonizing the EP<sub>2</sub> receptor with an EP<sub>2</sub> receptor antagonist and inhibiting cyclooxygenase COX-2 with a Cox-2 inhibitor.

**Claim 18. (Previously Presented)** The method according to claim 17, wherein said EP<sub>2</sub> receptor antagonist is selective for said EP<sub>2</sub> receptor and said Cox-2 inhibitor is selective for said Cox-2.